Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;40(1):30-41.
doi: 10.1038/s41587-021-01131-y. Epub 2021 Dec 20.

Single-cell immunology of SARS-CoV-2 infection

Yuan Tian  1   2 , Lindsay N Carpp  1 , Helen E R Miller  1 , Michael Zager  3 , Evan W Newell  4 , Raphael Gottardo  5   6   7
Affiliations
Review

Single-cell immunology of SARS-CoV-2 infection

Yuan Tian et al. Nat Biotechnol. 2022 Jan.

Abstract

Gaining a better understanding of the immune cell subsets and molecular factors associated with protective or pathological immunity against severe acute respiratory syndrome coronavirus (SARS-CoV)-2 could aid the development of vaccines and therapeutics for coronavirus disease 2019 (COVID-19). Single-cell technologies, such as flow cytometry, mass cytometry, single-cell transcriptomics and single-cell multi-omic profiling, offer considerable promise in dissecting the heterogeneity of immune responses among individual cells and uncovering the molecular mechanisms of COVID-19 pathogenesis. Single-cell immune-profiling studies reported to date have identified innate and adaptive immune cell subsets that correlate with COVID-19 disease severity, as well as immunological factors and pathways of potential relevance to the development of vaccines and treatments for COVID-19. For facilitation of integrative studies and meta-analyses into the immunology of SARS-CoV-2 infection, we provide standardized, download-ready versions of 21 published single-cell sequencing datasets (over 3.2 million cells in total) as well as an interactive visualization portal for data exploration.

PubMed Disclaimer

Conflict of interest statement

Competing interests

R.G. has received consulting income from Juno Therapeutics, Takeda, Infotech Soft, Celgene, Merck and has received research support from Janssen Pharmaceuticals and Juno Therapeutics, and declares ownership in CellSpace Biosciences. E.W.N is a co-founder, advisor and shareholder of ImmunoScape Pte. Ltd. and is an advisor for Neogene Therapeutics and Nanostring Technologies.

Figures

Figure 1.
Figure 1.
Visual representation of characteristics of the 64 published articles or publicly posted preprints on COVID-19 that have used one or more single-cell technologies (March 2020 – March 2021). (a,b) Scatter plots showing the number of participants versus (a) the number of flow cytometry markers or (b) the number of cells for which data are available in each study. Each symbol represents a dataset using one of the single-cell technologies from a single article/preprint. Opacity indicates dataset availability to the public (light, no; dark, yes), shape indicates whether the dataset has longitudinal data (circle, no; triangle, yes), and color indicates assay type [(a) red, flow cytometry; cyan, mass cytometry; (b) red, repertoires; gold, RNA; green, RNA plus protein; blue, RNA plus protein plus +repertoires; and magenta, RNA plus repertoires].
Figure 2.
Figure 2.
Visual representation of single-cell transcriptomics data. (a) Plots showing the distribution of age (left panel) and sex (right panel) among individuals included in the collected 21 datasets. (b) Bar plot showing the number of samples per tissue type among the collected 21 datasets. (c) Uniform manifold approximation and projection (UMAP) plots showing the projection of over 2.5 million single cells from 16 PBMC and whole blood datasets (the latter minus neutrophils and basophils) mapped to the Seurat CITE-seq reference, colored and labeled by reference-defined cell type annotations at level 1 (left panel), level 2 (middle panel), and level 3 (right panel) granularity. (D) Box plots showing the frequencies of CD4+ T cells, CD8+ T cells, mucosal-associated invariant T (MAIT) cells, CD56bright NK cells, CD16+ monocytes, and CD14+ monocytes among samples grouped by disease severity and time points for COVID-19 samples. Samples from Arunachalam et al. (enriched for DCs), Meckiff et al. (enriched for antigen-specific CD4+ T cells), Kusnadi et al. (enriched for antigen-specific CD8+ T cells), and Bacher et al. (enriched for antigen-specific CD4+ T cells) were excluded. Early, <= 8 days post symptom onset; intermediate, > 8 and <= 15 days post symptom onset; late, > 15 days post symptom onset. Statistical significance between mild and severe was determined by Wilcoxon test. *: p <= 0.05, **: p <= 0.01, ***: p <= 0.001, ****: p <= 0.0001.
Figure 3.
Figure 3.
An example screenshot of the visualization portal. The website provides visualization of 21 individual datasets and the merged dataset consisting of 16 datasets. The UMAP plot showing the merged dataset consisting of over 2.5 million cells mapped to the human PBMC CITE-seq reference. The processed datasets can also be downloaded from the website at https://atlas.fredhutch.org/fredhutch/covid.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Joszt L. Fauci and Panel Discuss Ongoing Challenges of the COVID-19 Pandemic, and Lessons Learned. AJMC. [18 Feb 2021]. https://www.ajmc.com/view/fauci-and-panel-discuss-ongoing-challenges-of-.... Quote from the 2020 CHEST Annual Meeting Keynote Address by Dr. Anthony Fauci. 19 Oct 2020. Access date.
    1. World Health Organization Coronavirus disease (COVID-19) pandemic https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Last updated 6 Sept, 2021. Access date 6 Sept, 2021.
    1. Dai L & Gao GF Viral targets for vaccines against COVID-19. Nat Rev Immunol 21, 73–82 (2021). - PMC - PubMed
    1. Kim PS, Read SW & Fauci AS Therapy for Early COVID-19: A Critical Need. JAMA 324, 2149–2150 (2020). - PubMed
    1. Weinreich DM et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 384, 238–251 (2021). - PMC - PubMed

Publication types